FN1 and neoplasm: Currently, many efforts are ongoing to develop small molecule inhibitors targeting TG2-FN interface (Yakubov et al., 2014; Sima et al., 2019), block FN extra domains particularly ED-B (Menrad and Menssen, 2005; El-Emir et al., 2007; Sauer et al., 2009; Schliemann et al., 2009; Zhang et al., 2022) or impair FN exocytosis to reduce tumor migration and invasion (Park et al., 2022).